Drugs / Meplazumab
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04327310 | Mar → Dec 2023 | Plasmodium falciparum malaria | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Withdrawn | No outcome recorded |
| Phase 1 | NCT04369586 | Apr → Aug 2020 | — | Xijing Hospital | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04275245 | Feb → Mar 2020 | COVID-19 | Tang-Du Hospital | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06040346 | Apr 2024 → Aug 2025 overdue | Plasmodium falciparum malaria | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Active not recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05113784 | Jan → Sep 2022 | COVID-19 | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 2/3 | NCT04586153 | Feb 2021 → Dec 2022 | COVID-19 | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT05679479 | Jan 2024 | COVID-19 | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Completed | Missed primary |
| Phase 3 | NCT05679492 | May → Sep 2023 | COVID-19 | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Withdrawn | No outcome recorded |
| Phase 3 | NCT05813587 | Mar → Sep 2023 | post-COVID-19 disorder | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meplazumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05679479 ↗ |
| Known as | Ketantin | “Meplazumab (Ketantin®) is a lyophilized powder for injection of small volume.” NCT04327310 ↗ |
| Action | Inhibit | “which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby...” NCT04586153 ↗ |
| Modality | Monoclonal antibody | “humanized MAb against CD147” NCT04275245 ↗ |
| Route | Intravenous | “by intravenous(IV) infusion” NCT04275245 ↗ |